Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Adamis Pharmaceuticals sends letter to shareholders regarding board memebers » 08:08
07/01/21
07/01
08:08
07/01/21
08:08
ADMP

Adamis Pharmaceuticals

$1.11 /

-0.035 (-3.07%)

Adamis Pharmaceuticals…

Adamis Pharmaceuticals issued the following letter to stockholders: "The Board of Directors (the "Board") appreciates your continued investment in Adamis Pharmaceuticals Corporation ("Adamis" or the "Company" or "we"). The Board also appreciates the feedback that many stockholders have provided in recent weeks. As we work to position Adamis for long-term success, please trust that this input will be carefully assessed and factored into our go-forward plans. We are writing to you today to once again urge you to vote to re-elect all five members of the Board at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") on July 16, 2021. In our view, maintaining boardroom continuity can help the Company achieve the following: Support the ongoing Food and Drug Administration ("FDA") review of our ZIMHI(TM) New Drug Application. Advance our Phase 2/3 trial for examining the effects of Tempol on COVID-19. Support ongoing efforts to obtain government funding for Tempol. Advance the Investigational New Drug for Tempol's use in radiation dermatitis. Demonstrate a further increase in SYMJEPI(R) sales. Maintain a strong capital position and healthy balance sheet. Prioritize progress across our entire product pipeline... Mr. Hammann initially demanded a lucrative and unjusitified paid consulting agreement - which would have been paid for with stockholders' capital - before he was even a stockholder of the Company. Mr. Hammann threatened to make books and records demands and to run a campaign against the Board if we did not quickly agree to award him the demanded consulting agreement. Mr. Hammann has no operating experience in the biotechnology or pharmaceutical sector. Mr. Hammann has no experience as a director or executive of a public company. Mr. Hammann has a history of filing serial lawsuits and being a vexatious litigator. Mr. Hammann submitted an untimely and invalid notice of director nominations. His nominations will not be accepted at the Annual Meeting. Mr. Hammann unsuccessfully sued the Company in an attempt to delay the Annual Meeting and forced us to expend precious stockholder capital on fending off litigation. Mr. Hammann has no plan for the Company. We hope stockholders recognize that supporting Mr. Hammann's misguided campaign would be akin to taking what we believe is a major risk. Rather than support a litigious stockholder that is waging a costly and distracting battle with the Company, we urge you to reject his efforts by voting to re-elect your current Board. Once again, we thank you for your investment in Adamis. We firmly believe that the Company is on the right path now that we have tangible pipeline momentum. Vote on the WHITE proxy card to elect our full five-member slate and help us sustain the Company's progress."

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
$1.11 /

-0.035 (-3.07%)

ADMP Adamis Pharmaceuticals
$1.11 /

-0.035 (-3.07%)

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
$1.11 /

-0.035 (-3.07%)

ADMP Adamis Pharmaceuticals
$1.11 /

-0.035 (-3.07%)

Hot Stocks
Adamis Pharmaceuticals issues letter to stockholders regarding Tempol treatment » 07:07
06/28/21
06/28
07:07
06/28/21
07:07
ADMP

Adamis Pharmaceuticals

$1.22 /

+0.105 (+9.42%)

Adamis Pharmaceuticals…

Adamis Pharmaceuticals issued the below letter to stockholders. The letter said, "The Board of Directors (the "Board") appreciates your continued investment in Adamis Pharmaceuticals Corporation ("Adamis" or the "Company"). Ahead of our Annual Meeting of Stockholders on July 16th (the "Annual Meeting"), we want to once again urge you to vote to re-elect all five members of the Board. We believe maintaining continuity in the boardroom is critical as Adamis focuses on driving pipeline progress and initiating its phase 2/3 trial for examining the effectiveness of Tempol in the treatment of COVID-19. We recognize that the road to value creation in the biotechnology industry often includes detours and hurdles. Like many other companies pursuing new drugs and treatments for complex diseases and conditions, Adamis has certainly encountered its own disappointments and setbacks in the course of working to develop, secure approvals for and commercialize our products. The Board is grateful to you for sticking with us - and we want you to know we are listening to you and learning from your feedback... Notably, we believe our role in trying to fight the pandemic is becoming even more vital now that the Delta variant is rapidly spreading across the globe. We believe our efforts related to Tempol are providing us with a unique opportunity to pursue value for society and our stockholders. The Board is focused on this opportunity. Regrettably, Jerald A. Hammann - an opportunistic holder of 1,000 shares with no biopharmaceutical expertise, no public company experience and no articulated strategy - is continuing to wage costly litigation and is attempting to run a slate of directors to take control of the Board at this year's Annual Meeting. Mr. Hammann is doing this despite the fact that the Delaware Court of Chancery ruled against his effort to enjoin the Company from sending you our proxy materials, soliciting your votes and holding our Annual Meeting as currently scheduled. We contend that Mr. Hammann's seemingly unlawful, disingenuous and disruptive efforts are a threat to Adamis and its stockholders. The Board urges stockholders to reject Mr. Hammann's campaign of attacks, distortions and mischaracterizations. Mr. Hammann has no plan or relevant operating background in the biotechnology industry. It is not the time to veer off the Company's path and risk undermining initiatives pertaining to Tempol and our other product initiatives. Once again, we thank you for your investment in Adamis. We encourage you to vote on the WHITE proxy card to elect our full five-member slate and help us sustain the Company's momentum."

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
$1.22 /

+0.105 (+9.42%)

ADMP Adamis Pharmaceuticals
$1.22 /

+0.105 (+9.42%)

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
$1.22 /

+0.105 (+9.42%)

ADMP Adamis Pharmaceuticals
$1.22 /

+0.105 (+9.42%)

Hot Stocks
Adamis Pharmaceuticals provides update on clinical trial progress for Tempol » 07:33
06/11/21
06/11
07:33
06/11/21
07:33
ADMP

Adamis Pharmaceuticals

$1.00 /

-0.075 (-6.98%)

Adamis Pharmaceuticals…

Adamis Pharmaceuticals announced that clinical trial start-up activities are underway for examining the effects of Tempol, which is the company's experimental drug, in the treatment of COVID-19. Adamis is carrying out these activities with a large clinical research organization. The goal of the trial - entitled "A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol on Preventing COVID-19 Related Hospitalization in Subjects with COVID-19 Infection" - is to examine the safety and activity of Tempol in COVID-19 patients early in the infection. In addition to safety, the study will examine markers of inflammation, symptoms, and the rate of hospitalization for patients taking Tempol versus placebo. Dennis Carlo, CEO of Adamis, commented: "We believe that additional treatment modalities are sorely-needed for COVID-19 due to the surge of virus variants. Because of Tempol's mechanism of action, it may inhibit viral replication of all current and future variants of the virus. The results of the NIH studies further support the importance of our clinical trial. The addition of a well-respected data safety monitoring board to the well-designed trial should further increase the likelihood of meaningful clinical data. We look forward to carrying out this trial and helping produce another potential breakthrough treatment for COVID-19."

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
$1.00 /

-0.075 (-6.98%)

ADMP Adamis Pharmaceuticals
$1.00 /

-0.075 (-6.98%)

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
$1.00 /

-0.075 (-6.98%)

ADMP Adamis Pharmaceuticals
$1.00 /

-0.075 (-6.98%)

Hot Stocks
Adamis Pharmaceuticals provides update on ZIMHI » 07:37
06/09/21
06/09
07:37
06/09/21
07:37
ADMP

Adamis Pharmaceuticals

$1.00 /

-0.0422 (-4.06%)

Adamis Pharmaceuticals…

Adamis Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for review the company's resubmitted New Drug Application for ZIMHI, which is its higher naloxone injection product candidate for the treatment of opioid overdose. Adamis received FDA correspondence relating to the company's NDA, stating that the Agency had completed its filing review and had determined that the NDA was sufficiently complete to permit a substantive review. The FDA also provided a target action date under the Prescription Drug User Fee Act of November 12, 2021. "We are pleased with the FDA's decision to accept for review our NDA for ZIMHI. I believe this underscores the need for additional treatment alternatives for narcotic overdose," said Dr. Dennis J. Carlo, President and CEO of Adamis Pharmaceuticals. "We look forward to working collaboratively with the FDA during the review process to support the case for approval of ZIMHI."

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
$1.00 /

-0.0422 (-4.06%)

ADMP Adamis Pharmaceuticals
$1.00 /

-0.0422 (-4.06%)

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
$1.00 /

-0.0422 (-4.06%)

ADMP Adamis Pharmaceuticals
$1.00 /

-0.0422 (-4.06%)

Hot Stocks
Adamis highlights NIH study identifying Tempol as potential antiviral for COVID » 07:43
06/07/21
06/07
07:43
06/07/21
07:43
ADMP

Adamis Pharmaceuticals

$1.00 /

-0.13 (-11.50%)

Adamis Pharmaceuticals…

Adamis Pharmaceuticals Corporation highlighted that the National Institutes of Health has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-19. According to a study of cell cultures conducted by NIH researchers, Tempol demonstrated an ability to limit SARS-CoV-2 infection by impairing the activity of a viral enzyme known as RNA replicase. The NIH researchers also found that Tempol "doses used in their antiviral studies could be likely achieved in tissues that are the primary targets for the virus." The June 3rd announcement issued by the NIH noted that the study team was led by researchers from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The team also included researchers from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases and the National Institute of Neurological Disorders and Stroke. Additional study details disclosed include: Researchers discovered Tempol's effectiveness by assessing a basic question of how the virus utilizes its RNA replicase, which is an enzyme that enables SARS-CoV-2 to replicate its genome and make copies of itself when inside a cell. Researchers tested if RNA replicase and the enzyme's nsp12 sub-unit require iron-sulfur clusters for structural support. Findings indicate that the SARS-CoV-2 RNA replicase requires two iron-sulfur clusters to function optimally. Earlier studies mistakenly identified these iron-sulfur cluster binding sites as zinc-binding sites. Researchers found that Tempol can degrade iron-sulfur clusters. Researchers intend to conduct additional studies and will evaluate Tempol in a clinical study for COVID-19. The NIH study follows studies conducted in collaboration with Galveston National Laboratory and the University of Texas Medical Branch at Galveston. These studies entailed hamsters being challenged with SARS-CoV-2 receiving TEMPOL as a treatment. The TEMPOL-treated animals showed decreased lung inflammation compared to controls. Earlier this year, Adamis announced that in-vitro inflammatory cytokine data from a study done in collaboration with Stanford University showed that TEMPOL significantly inhibited the release of multiple inflammatory cytokines from activated immune cells of COVID-19 patients. The Stanford study suggested Tempol may prevent the cytokine storm observed in COVID-19 patents. The Company believes that the results from the NIH study also support the design and implementation of the protocol in Adamis' Investigational New Drug Application to study Tempol in early COVID-19 infection. The goal of this study titled, "A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol on Preventing COVID-19 Related Hospitalization in Subjects with COVID-19 Infection," is to examine the safety and activity of Tempol in COVID-19 patients early in the infection. In addition to safety, the study will examine markers of inflammation, COVID-19 symptoms, and the rate of hospitalization for patients taking Tempol versus placebo early in COVID-19 infection. Adamis has previously licensed exclusive worldwide rights under patents, patent applications and related know-how to use Tempol for the treatment of respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19, as well as the use of Tempol as a therapeutic for reducing radiation-induced dermatitis in patients undergoing treatment for cancer.

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
$1.00 /

-0.13 (-11.50%)

ADMP Adamis Pharmaceuticals
$1.00 /

-0.13 (-11.50%)

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
$1.00 /

-0.13 (-11.50%)

ADMP Adamis Pharmaceuticals
$1.00 /

-0.13 (-11.50%)

Hot Stocks
Adamis Pharmaceuticals up 45% to $1.02 after NIH report on Tempol » 14:13
06/03/21
06/03
14:13
06/03/21
14:13
ADMP

Adamis Pharmaceuticals

/

+

Adamis shares have jumped…

Adamis shares have jumped 32c, or 45%, to $1.02 after the NIH said a study of cell cultures suggested that the experimental drug Tempol may be "a promising oral antiviral treatment" for COVID-19.

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
/

+

ADMP Adamis Pharmaceuticals
/

+

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
/

+

ADMP Adamis Pharmaceuticals
/

+

Hot Stocks
NIH researchers identify Adamis' Tempol as potential antiviral drug for COVID-19 » 14:11
06/03/21
06/03
14:11
06/03/21
14:11
ADMP

Adamis Pharmaceuticals

$0.70 /

+0.0009 (+0.13%)

The experimental drug…

The experimental drug Tempol may be a promising oral antiviral treatment for COVID-19, suggests a study of cell cultures by researchers at the National Institutes of Health, the NIH announced. Tempol can limit SARS-CoV-2 infection by impairing the activity of a viral enzyme called RNA replicase, according to work led by researchers at NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development that appears in "Science," the NIH stated in a press release. Dennis Carlo, Ph.D., President and CEO of Adamis Pharmaceuticals, stated on June 1: "We have also been preparing to begin patient enrollment in a Phase 2/3 clinical trial to evaluate the use of Tempol in patients with COVID-19." Reference Link

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
$0.70 /

+0.0009 (+0.13%)

ADMP Adamis Pharmaceuticals
$0.70 /

+0.0009 (+0.13%)

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
$0.70 /

+0.0009 (+0.13%)

ADMP Adamis Pharmaceuticals
$0.70 /

+0.0009 (+0.13%)

Hot Stocks
Adamis says bulk of Q1 focus on NDA for ZIMHI naloxone for opioid overdose » 07:44
06/01/21
06/01
07:44
06/01/21
07:44
ADMP

Adamis Pharmaceuticals

/

+

Adamis Pharmaceuticals…

Adamis Pharmaceuticals the following business update. "The bulk of our focus during the first quarter was on preparing for the Type-A meeting with the FDA regarding our New Drug Application for ZIMHI naloxone injection product intended for the treatment of opioid overdose. Based on feedback received in that meeting, we resubmitted the NDA in May," stated Dennis J. Carlo, Ph.D., President and Chief Executive Officer of Adamis Pharmaceuticals. "We have also been preparing to begin patient enrollment in a Phase 2/3 clinical trial to evaluate the use of Tempol in patients with COVID-19."

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
/

+

ADMP Adamis Pharmaceuticals
/

+

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
/

+

ADMP Adamis Pharmaceuticals
/

+

Hot Stocks
Adamis Pharmaceuticals receives deficiency letter from Nasdaq » 16:05
05/28/21
05/28
16:05
05/28/21
16:05
ADMP

Adamis Pharmaceuticals

/

+

Adamis Pharmaceuticals…

Adamis Pharmaceuticals Corporation announced that, as expected, on May 25, 2021, it received a standard notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the company that, because the company did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021, the company is no longer in compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission.

ShowHide Related Items >><<
ADMP Adamis Pharmaceuticals
/

+

ADMP Adamis Pharmaceuticals
/

+

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
  • 29
    Jan
  • 18
    Sep
ADMP Adamis Pharmaceuticals
/

+

ADMP Adamis Pharmaceuticals
/

+

On The Fly
Fly Intel: Pre-market Movers » 09:11
05/25/21
05/25
09:11
05/25/21
09:11
MRNA

Moderna

$164.12 /

+2.565 (+1.59%)

, PIRS

Pieris Pharmaceuticals

$1.84 /

-0.08 (-4.17%)

, SHAK

Shake Shack

$84.59 /

+0.7 (+0.83%)

, IMBI

iMedia Brands

$7.92 /

+0.32 (+4.21%)

, MMYT

MakeMyTrip

$25.86 /

-0.02 (-0.08%)

, JYNT

Joint Corp.

$58.19 /

+2.76 (+4.98%)

, DY

Dycom

$83.01 /

-1.29 (-1.53%)

, RIDE

Lordstown Motors

$9.70 /

+0.1 (+1.04%)

, API

Agora

$40.30 /

-1.18 (-2.84%)

, ADMP

Adamis Pharmaceuticals

/

+

, WOOF

Petco

$24.59 /

-0.05 (-0.20%)

, RHHBY

Roche

$43.16 /

-0.09 (-0.21%)

Check out this morning's…

ShowHide Related Items >><<
WOOF Petco
$24.59 /

-0.05 (-0.20%)

SHAK Shake Shack
$84.59 /

+0.7 (+0.83%)

RIDE Lordstown Motors
$9.70 /

+0.1 (+1.04%)

RHHBY Roche
$43.16 /

-0.09 (-0.21%)

PIRS Pieris Pharmaceuticals
$1.84 /

-0.08 (-4.17%)

MRNA Moderna
$164.12 /

+2.565 (+1.59%)

JYNT Joint Corp.
$58.19 /

+2.76 (+4.98%)

IMBI iMedia Brands
$7.92 /

+0.32 (+4.21%)

DY Dycom
$83.01 /

-1.29 (-1.53%)

API Agora
$40.30 /

-1.18 (-2.84%)

ADMP Adamis Pharmaceuticals
/

+

MRNA Moderna
$164.12 /

+2.565 (+1.59%)

05/21/21 Piper Sandler
Piper says overseas approvals providing 'second leg of growth' for Moderna
05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
05/07/21 Goldman Sachs
Moderna price target raised to $228 from $206 at Goldman Sachs
05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
PIRS Pieris Pharmaceuticals
$1.84 /

-0.08 (-4.17%)

SHAK Shake Shack
$84.59 /

+0.7 (+0.83%)

05/25/21 Wedbush
Shake Shack upgraded to Outperform from Neutral at Wedbush
05/25/21 Goldman Sachs
Shake Shack upgraded to Buy from Neutral at Goldman Sachs
05/10/21 Deutsche Bank
Shake Shack price target lowered to $95 from $107 at Deutsche Bank
04/12/21 JPMorgan
Shake Shack price target lowered to $80 from $90 at JPMorgan
IMBI iMedia Brands
$7.92 /

+0.32 (+4.21%)

03/23/21 Lake Street
iMedia Brands price target raised to $15 from $13 at Lake Street
02/11/21 DA Davidson
iMedia Brands price target raised to $19 from $12 at DA Davidson
02/10/21 DA Davidson
iMedia Brands price target raised to $19 from $12 at DA Davidson
11/25/20 Lake Street
iMedia Brands pullback after 'strong' Q3 a buying opportunity, says Lake Street
MMYT MakeMyTrip
$25.86 /

-0.02 (-0.08%)

02/16/21 BofA
MakeMyTrip upgraded to Neutral from Underperform at BofA
02/16/21 BofA
MakeMyTrip upgraded to Neutral from Underperform at BofA
01/12/21 Citi
MakeMyTrip price target raised to $35 from $23 at Citi
JYNT Joint Corp.
$58.19 /

+2.76 (+4.98%)

04/28/21 B. Riley
Joint Corp. price target raised to $60 from $47 at B. Riley
04/07/21 DA Davidson
Joint Corp. price target raised to $57 from $54 at DA Davidson
03/08/21 DA Davidson
Joint Corp. price target raised to $54 from $33 at DA Davidson
03/05/21 Lake Street
Joint Corp. price target raised to $60 from $35 at Lake Street
DY Dycom
$83.01 /

-1.29 (-1.53%)

04/06/21 DA Davidson
Dycom well aligned given private capital and federal subsidies, says DA Davidson
03/04/21
Fly Intel: Top five analyst downgrades
03/04/21 Craig-Hallum
Dycom price target raised to $110 from $72 at Craig-Hallum
03/04/21 DA Davidson
Dycom price target raised to $105 from $80 at DA Davidson
RIDE Lordstown Motors
$9.70 /

+0.1 (+1.04%)

05/25/21 Morgan Stanley
Lordstown Motors price target lowered to $8 from $12 at Morgan Stanley
05/20/21
Fly Intel: Top five analyst downgrades
05/20/21 Wolfe Research
Wolfe downgrades Lordstown to sell with $1 target after Ford reveal
05/20/21 Wolfe Research
Lordstown Motors downgraded to Underperform from Peer Perform at Wolfe Research
API Agora
$40.30 /

-1.18 (-2.84%)

05/10/21 Macquarie
Agora price target lowered to $60 from $80 at Macquarie
03/23/21 Macquarie
Agora initiated with an Outperform at Macquarie
01/05/21 China Renaissance
Agora initiated with a Buy at China Renaissance
11/17/20 Needham
Agora price target lowered to $50 from $55 at Needham
ADMP Adamis Pharmaceuticals
/

+

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
WOOF Petco
$24.59 /

-0.05 (-0.20%)

05/21/21 Baird
Petco weakness a buying opportunity, says at Baird
05/20/21 Baird
Petco pullback a buying opportunity, says Baird
05/20/21 Wells Fargo
Wells would be buyers of Petco amid 'inexplicable' post-earnings selloff
05/18/21 Credit Suisse
Petco assumed with a Neutral at Credit Suisse
RHHBY Roche
$43.16 /

-0.09 (-0.21%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
WOOF Petco
$24.59 /

-0.05 (-0.20%)

SHAK Shake Shack
$84.59 /

+0.7 (+0.83%)

RIDE Lordstown Motors
$9.70 /

+0.1 (+1.04%)

RHHBY Roche
$43.16 /

-0.09 (-0.21%)

PIRS Pieris Pharmaceuticals
$1.84 /

-0.08 (-4.17%)

MRNA Moderna
$164.12 /

+2.565 (+1.59%)

MMYT MakeMyTrip
$25.86 /

-0.02 (-0.08%)

JYNT Joint Corp.
$58.19 /

+2.76 (+4.98%)

IMBI iMedia Brands
$7.92 /

+0.32 (+4.21%)

DY Dycom
$83.01 /

-1.29 (-1.53%)

API Agora
$40.30 /

-1.18 (-2.84%)

  • 27
    May
  • 18
    Feb
  • 29
    Jan
  • 14
    Jan
  • 18
    Sep
  • 26
    Aug
  • 26
    Jun
RIDE Lordstown Motors
$9.70 /

+0.1 (+1.04%)

RHHBY Roche
$43.16 /

-0.09 (-0.21%)

MRNA Moderna
$164.12 /

+2.565 (+1.59%)

WOOF Petco
$24.59 /

-0.05 (-0.20%)

SHAK Shake Shack
$84.59 /

+0.7 (+0.83%)

RIDE Lordstown Motors
$9.70 /

+0.1 (+1.04%)

RHHBY Roche
$43.16 /

-0.09 (-0.21%)

MRNA Moderna
$164.12 /

+2.565 (+1.59%)

JYNT Joint Corp.
$58.19 /

+2.76 (+4.98%)

IMBI iMedia Brands
$7.92 /

+0.32 (+4.21%)

DY Dycom
$83.01 /

-1.29 (-1.53%)

ADMP Adamis Pharmaceuticals
/

+

WOOF Petco
$24.59 /

-0.05 (-0.20%)

SHAK Shake Shack
$84.59 /

+0.7 (+0.83%)

RIDE Lordstown Motors
$9.70 /

+0.1 (+1.04%)

MRNA Moderna
$164.12 /

+2.565 (+1.59%)

API Agora
$40.30 /

-1.18 (-2.84%)

ADMP Adamis Pharmaceuticals
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.